| Literature DB >> 33195331 |
Ayelet Barash1,2, Yossy Machluf1, Ilana Ariel3, Yaron Dekel1,4.
Abstract
Diverse populations worldwide are differentially affected by coronavirus disease 2019 (COVID-19). While socioeconomic background has been studied extensively, little is known about the genetic variation underlying this phenomenon. This study is aimed at examining the genetic basis behind the great discrepancies among diverse ethnic groups in terms of COVID-19 susceptibility for viral infection, disease prognosis, and mortality. To this end, in silico analysis of single-nucleotide polymorphisms (SNPs) within regulatory sequences of the human angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2)-the virus's gateway to host cells-and their plausible implications on expression levels was conducted. We provide indication that the variation in the human ACE2 and TMPRSS2 regulatory sequences is likely to be involved in and contribute to this phenomenon. SNPs that are abundant in the more susceptible populations introduce binding sites (BSs) for transcription factors or they may invalidate BSs for transcription repressor-both may enhance target gene (ACE2 or TMPRSS2) expression in the relevant target tissues. SNPs that are abundant in the more resistant populations may invalidate BSs for a transcriptional repressor or they may introduce BSs for a transcriptional repressor or initiator of mRNA degradation, which may reduce target gene expression levels. This aspect, when added to the socioeconomic factors, can be a cause for the divergent prevalence of the disease and the different mortality rates within diverse populations. This demonstration may call for a shift in the paradigm of searching for COVID-19 biomarkers, such that SNPs within regulatory sequences should be of high importance.Entities:
Keywords: ACE2; COVID-19; SNP; TMPRSS2; biomarkers; regulatory sequence elements
Year: 2020 PMID: 33195331 PMCID: PMC7661736 DOI: 10.3389/fmed.2020.582793
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
REFSEQ ID (rs), chromosomal location, occurrence, ethnicity, added/subtracted transcription factor (TF) prediction, and estimated expression outcome in the human angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2) proximal, and core promoter sequence.
| Human | rs4646114; C>T | chrX:15601259 | 0.2–2.2% | 5.0–7.2% | 0% | 0% | NF-AT1, YY1 | Elevated transcription |
| rs536092258, C>A | chrX:15601214 | 0.4% | 0% | 2.1% | 0% | PR-B | mRNA degradation | |
| rs4646115, T>C | chrX:15601146 | 0.1–0.6% | 1.4–1.8% | 0% | 0% | C/EBPβ↑ GR-β | Elevated transcription | |
| rs370596467, T>C | chrX:15600945 | 0.02–0.05% | 0% | 0.1–0.2% | 0.1–0.4% | RXR-α, VDR↑ XBP1 ↓ | Transcription suppression | |
| Human | rs61299115, delGGCGCAGCGC CGCGGCGCAGCGC>CGC | chr21:41508410-19 | 24.6–36.3% | 29.7–32.5% | 22.4% | 0.9–1.8% | 2X GCF ↓ | Elevated transcription |
| rs11088551, A>G | chr21:41508389 | 24.6–36.4% | 29.7–32.6% | 22.4% | 1.0%-1.8% | AP2α ↑ | Elevated transcription | |
| rs4303794, A>C | chr21: 41508379 | 24.6–36.4% | 29.7–32.6% | 22.4% | 1.0–1.9% | PAX5 ↑ | Elevated transcription | |
Only single-nucleotide polymorphisms (SNPs) above 1/1,000 occurrences are included.
pre-mature mRNA.
A TF that is less relevant due to location/functional constraints.
Figure 1Schematic representation of the human ACE2 (A) and TMPRSS2 (B) genes, the relevant SNPs and their predicted implication on mRNA level.
Expression levels of angiotensin-converting enzyme 2 (ACE2), transmembrane protease, serine 2 (TMPRSS2), and related transcription factors in different tissues.
| Gastrointestinal and Proximal Digestive Tract | Moderate | Moderate | Moderate | Moderate | Moderate | ||||||
| Lung | Low | Moderate | Moderate | Low | Moderate | Moderate | Moderate | N/A | Low | ||
| Bone marrow, Lymphoid tissues, Thyroid gland | Low | Low | Moderate | Moderate | Moderate | ||||||
| Kidney and urinary bladder | Moderate | Moderate | Moderate | Low | Low | Moderate | N/A | Low | |||
| Liver and gall bladder | Moderate | Low | N/A | N/A | N/A | Moderate | Moderate | N/A | Low | ||
| Skin | Low | N/A | Low | Low | Low | Low | |||||
| Male tissues | Moderate | N/A | Low | Low | Moderate | Moderate | Moderate | Low | |||
| Muscle tissue | N/A | Moderate | Moderate | Low | Low | N/A | N/A | Low | |||
The level of expression was determined by normalized expression levels from three transcriptome datasets (HPA, GTEx, and FANTOM5). Tissues that are not relevant to COVID-19 are not noted.